Author:
Wolf M.,Schneider P.,Budach V.,Thomas M.
Publisher
Springer Berlin Heidelberg
Reference233 articles.
1. Abratt RP, Bezwoda WR, Falkson G et al (1994) Efficacy and safety profile of gemcitabine in non-small cell lung cancer: a phase II study. J Clin Oncol 12:1535–1450
2. Abratt RP, Szczesna A, Mattson K et al (2004) Vinorelbine (NVB)-carboplatin (CBDCA) vs non-platinum doublets in inoperable non-small cell lung cancer (NSCLC) patients (pts)-final results of the Glob 2 phase III with patient benefit analysis. Proc ASCO, abstr 7016
3. Adjei A, Mauer A, Bruzek L et al (2003) Phase II trial of the farnesyl transferase inhibitor R115777 in patients with advanced NSCLC. J Clin Oncol 21:1760–1766
4. Akerly W, Glantz M, Choy H et al (1998) Phase I Trial of Weekly Paclitaxel in Advanced Lung Cancer. J Clin Oncol 16:153–158
5. Albain KS, Crowley JJ, Turrisi AT et al (1997) Concurrent cisplatin/etoposide plus radiotherapy (PE + RT) for pathologic stage (path TN) IIIB non-small cell lung cancer (NSCLC): a Southwest Oncology Group (SWOG) phase-II-study (S9019) Proc ASCO 16: 1600